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the hemolytic assay. However, this assay is not applicable to the lectin pathway, thus impeding the
understanding of complement inhibitors against the overall function of the complement system. The main
objective of our study was to develop a speciﬁc enzyme-linked immunosorbent assay (ELISA) as an
alternative method to assess the anti-complement activity, particularly against the lectin pathway. By
using respective coating substrates against different activation pathways, followed by capturing the stable
C3c fragments, our ELISA method can be used to screen complement inhibitors against the classical
pathway and the lectin pathway. The inhibitory effect of suramin on the classical pathway, as measured by
our hemolytic assay is consistent with previous reports. Further assessment of suramin and Bupleurum
polysaccharides against the lectin pathway showed a good reproducibility of the method. Comparison of
the lectin pathway IC50 between Bupleurum smithii var. parvifolium polysaccharides (1.055 mg/mL) and
Bupleurum chinense polysaccharides (0.98 mg/mL) showed that, similar to the classical and alterative
pathway, these two Bupleurum polysaccharides had comparable anti-complementary properties against the4
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As one of the major effector mechanisms of innate immunity, the
complement system is involved in a broad range of physiological
and pathological processes, such as clearance of immune com-
plexes and chronic inﬂammation1. Over the past decades, research-
ers have shown that besides its obvious roles in host defense, the
complement system also closely interacts with other cascade
effector systems, for example, the coagulation system2. By
participating in such diverse processes, the intricate complement
system builds up a delicate balance that is tightly regulated.
However, without proper regulation, these cascades can generate a
lot of inﬂammatory factors, which could disrupt the homeostasis
and ultimately contribute to various immune, inﬂammatory and
neurodegenerative diseases3. Hence, in the past 10 years, there has
been a growing concern with an effort to develop therapeutics,
especially complement inhibitors that can block the complement
cascade and thus prevent the hyperactivity of various complement
components.
In order to discover complement inhibitors, more effective and
efﬁcient methods are required. The traditional hemolytic assay is
the most commonly used assay to determine the activity of
complement system via three pathways respectively, namely the
classical pathway (CP), alternative pathway (AP) and lectin
pathway (LP). Hemolysin sensitized sheep or rabbit erythrocytes
are mixed with compounds to be tested. The more active the
complement system, the more erythrocytes get lysed, i.e., less
serum is needed to lyse 50% of a ﬁxed amount of erythrocytes.
Although the hemolytic assay is simple and straightforward, the
shortcomings of the assay are also apparent. The LP is activated
when mannose-binding lectin (MBL) binds to one of its carbohy-
drate ligands on the bacterial surfaces. The binding subsequently
results in the association of two serine proteases: MASP-1 and
MASP-2 (MBL-associated serine proteases). However, the MBL-
MASP complex has a strong structural and functional similarity to
the C1 complex, thus leading to the interference of the CP
involved with the hemolytic MBL assay4. It has been shown that
this interference can result in approximately 25% overestimation
of MBL-mediated hemolysis or even false test results in patients
with MBL-deﬁcient genotypes5, unless certain antibodies, such as
anti-C1q antibodies, are added into the system to inhibit the CP
activation.
The clinical signiﬁcance of the LP is increasingly noticeable for
the past decades. Its importance is highlighted in anti-bacterial
infection, especially in earlier years of life before adaptive system
has been established6. Despite of its protective role, inappropriate
activation of the LP could result in some life-threatening disease,
such as ischemia-reperfusion injuries and kidney diseases7. There-
fore, the defect of hemolytic assay in the LP limits the overall
understanding of complement inhibitors, particularly against the
LP. So far, many polysaccharides extracted from various plants,
such as the Bupleurum chinense polysaccharides, have shown anti-complementary features against the CP and the AP, but their
efﬁcacy in the LP is still uncovered due to this defect8. Besides, as
the readout of the hemolytic assay is optical density (OD), controls
are always needed to eliminate the baseline OD of colored
compounds. In this case, hemolytic assay is not an ideal assay
for drug various screening as it requires substantial amount of
puriﬁed compounds.
Apart from the hemolytic assay, the complement function can
also be evaluated by means of the ELISA technique via anti-
bodies9–11. The sera investigated are incubated in microtiter plates
coated with solid-phase complement activators. Human IgG or
IgM, lipopolysaccharide (LPS) and mannan are used as activators
respectively for CP, AP and LP. A speciﬁc antibody against the
corresponding complement component (e.g., C3/C4) is then used
to detect the complement activation. Compared with hemolytic
assay, the ELISA allows for detection of complement activation
in all three pathways. Up to now, this method has only been
employed to determine the complement activation or deﬁciency in
biological samples from patients or model animals. Considering
that the ELISA assay has several washing steps, it can eliminate
the inﬂuence of compounds' color on the ﬁnal readout. Addition-
ally, the 96-well plate in which ELISA is carried out also meets the
requirement for high throughput screening.
As mentioned above, a speciﬁc antibody is needed in the
ELISA assay to capture a particular cleavage product to reﬂect the
degree of complement activation. All three pathways, though
activated by different substrates, converge at C3, resulting in the
formation of the activation products, C3a, C3b, C5a and then
ultimately the membrane attack complex (C5b-9)12. In contrast to
C5a fragment, which is highly active with a half-life less than
5 min13, various C3 activation products are readily detectable
as they remain for a few hours14. Recent ﬁndings indicate that
the stable C3 cleavage product C3c is a valuable marker for
inﬂammatory processes15. Based on this, we chose the C3c
complement fragment as an indicator of complement activation.
In this paper, we developed a C3c-based ELISA method
adapted from the protocol reported by Roos et al.4 and examined
if this modiﬁed assay could be used for the screening of
complement inhibitors, especially for the determination of anti-
complementary effects against the LP. Next, the described assay
was veriﬁed by determining the inhibitory effect of the known
anti-complement drugs suramin and Bupleurum polysaccharides
against the CP and the LP.2. Materials and methods
2.1. Animals
Male guinea pigs, 4 weeks old of (300750) g body weight, were
purchased from Slaccas-Shanghai Lab Animal Ltd. The guinea
pigs were kept under speciﬁc pathogen free and normal housing
Mulu Wu et al.318conditions with access to water and food. All experimental
protocols described in this study were approved by the Animal
Ethical Committee of School of Pharmacy, Fudan University.
2.2. Preparation of guinea pig serum
The guinea pigs were anesthetized and whole blood was collected
from the femoral artery. After that, the blood was incubated at 4 1C
for 1 h to allow clotting. 200 μL of Veronal buffer saline (VBS)-
washed (145 mmol/L NaCl, 1.8 mmol/L sodium barbiturate,
2.8 mmol/L barbiturate acid) and packed sheep red blood cells
were mixed with every 10 mL sera and spin for 10 min at 400 g.
The supernatant was collected and aliquots were stored at 80 1C
for further use.
2.3. C3c based ELISA
In general, ELISA was performed using 96 well microtiter plates
(Nunc) that were coated with 50 μL/well of different substrates
diluted in coating buffer (100 mmol/L Na2CO3/NaHCO3, pH 9.6).
After overnight incubation at 4 1C, the coated wells were washed
three times after which the nonspeciﬁc binding sites were blocked
with 1% bovine serum albumin (BSA) in PBS for 1 h at 37 1C. All
subsequent detection antibodies were diluted in PBS containing
0.05% Tween-20 and 1% BSA (PBS-T-BSA) unless otherwise
stated, and each step was followed by washing three times using
PBS-0.5% Tween-20. Subsequently, the guinea pig sera were
incubated at indicated dilutions for 1 h at 37 1C. After washing,
bound C3c was detected using diluted rabbit polyclonal anti-
human C3c antibodies (Abs) (Shanghai Long Island Biotec. Co.,
Ltd., D-3004), followed by horseradish peroxides (HRP)-conju-
gated anti-rabbit Abs (Shanghai Long Island Biotec Co., Ltd.,
P-0047) diluted in PBS-T-BSA, for 1 h at 37 1C respectively.
Enzyme activity of HRP was assessed by addition of o-phenylene-
diamine and H2O2. After 15–30 min the reaction was stopped by
addition of 50 μL of 1 mol/L H2SO4 per well. OD was measured at
495 nm using a microtiter plate reader (Multiskan FC, Thermo
Scientiﬁc). The complement components of human and guinea pig
share structural similarity16, hence the anti-human C3c Abs used in
our assay were able to capture the bound C3c fragments in the guinea
pig serum. The coating concentration of IgM and LPS was
determined by using rabbit polyclonal anti-human C3c Abs and
HRP-conjugated anti-rabbit Abs at 1:1000. The optimization of
dilutions for these two Abs was carried out on the LP.
For the detection of CP activity, Nunc plates were coated with
human IgM at 5 μg/mL (Beijing Biosynthesis Biotechnology Co.,
Ltd., bs-0345P) overnight at 4 1C in coating buffer. Sera were
incubated in serial dilutions in BVBþþ (VBS containing
0.5 mmol/L MgCl2  6H2O, 1.5 mmol/L CaCl2, 0.05% Tween-20,
1% BSA, pH 7.5), for 1 h at 37 1C. For the LP, plates were coated
with mannan at 100 μg/mL (Sigma, M7504). After washing, serial
dilutions of sera in BVBþþ buffer were added and incubated for
1 h at 37 1C. For AP, plates were coated with LPS at 10 μg/mL
(Sigma, L3129). Sera were then incubated in GVB/Mg-EGTA
buffer (VBS containing 10 mmol/L EGTA, 5 mmol/L
MgCl2  6H2O, 0.05% Tween-20, 0.1% gelatin, pH 7.5).
2.4. Anti-complement activity determination
After optimization of the different parameters, conventional
complement inhibitors suramin (Sigma, S2671) and Bupleurumpolysaccharides were used for the validation and application of the
assay. Crude polysaccharides isolated from Bupleurum smithii var.
parvifolium (BPs, H2003121602) and Bupleurum chinense (BCPs,
20071015) were obtained from Prof. Daofeng Chen (Department
of Pharmacognosy, School of Pharmacy, Fudan University,
Shanghai, China). To determine the IC50 values against the CP
and LP, compounds were serially diluted and pre-incubated with
guinea pig sera for 45 min at 37 1C. The compound/sera mixture
was then added to the coated 96-well plates and processed as the
ELISA method described above. A tube of compound-free
BVBþþ buffer mixed with sera was also introduced in the
experiment as drug-free control (DFC). Background value (BG)
is determined as the OD value of wells added heat-inactivated fetal
bovine serum instead of guinea pig serum. All experiments were
carried out in triplicates in 96-well plate. The percentage of
inhibition is calculated according to the following equation:
Inhibition percentage ð%Þ ¼ 100–ðODsample–ODBGÞ=ðODDFC–ODBGÞ  100
The IC50 values determined by our ELISA were compared with
the results of the hemolytic assays published previously. The intra-
assay precision was assessed by analyzing 3 replicates of each
sample in a single run. The inter-assay precision was analyzed in
triplicate in 3 separate run.3. Results
3.1. Assay optimization
The assay used in this experiment was adapted from Roos et al.4
and Trouw et al.17. Considering the difference in coating substrate
and antibodies, various concentrations of all the reagents were
tested in order to optimize the assay. Different dilutions of sera
were used to represent varied complement level in the assay.
The mannan used for the LP was obtained from the same
supplier (Sigma-Aldrich, M7504) as Roos et al.4, thus the coating
concentration (100 μg/mL) was adopted from their work. For the
CP and the AP, three concentrations of IgM (5, 10 and 20 μg/mL)
and two concentrations of LPS (10 and 20 μg/mL) were tested.
Our results showed that different concentrations of IgM had
similar level of activation on the CP (Fig. 1a), suggesting that
the binding site on the microtiter plate was already saturated at
5 μg/mL. Similarly, 20 μg/mL LPS had comparable results as
10 μg/mL in the AP (Fig. 1b). Therefore, in our assay, the coating
concentration for IgM was chosen to be 5 μg/mL and 10 μg/mL
for LPS.
The second step of this assay was to determine the concen-
trations of rabbit polyclonal anti-human C3c Abs and HRP-
conjugated anti-rabbit Abs. These were carried out on the LP.
For rabbit polyclonal anti-human C3c Abs, three dilutions (1:1000,
1:2000 and 1:4000) were tested, keeping the HRP-conjugated anti-
rabbit Abs dilution constant at 1:1000 (Fig. 1c). To achieve high
intensity of color, 1:1000 of anti-human C3c Abs was determined
to be the best. Next, in order to decide the amount of HRP-
conjugated anti-rabbit Abs needed in the assay, the HRP-
conjugated anti-rabbit antibody dilutions were tested from 1:100
to 1:25,600 (data not shown) using IgG standard in the well-
established IgG ELISA assay in our lab (previously described in
Jiang et al.18). Dilutions of 1:800 and 1:1600 gave relatively
higher OD values with a broader linear range. Based on this result,
two dilutions of 1:1000 and 1:2000 were further veriﬁed using the
ELISA method for the LP as described above. As a result, 1:1000
Figure 1 Assay optimization. (a and b) Complement activation curve for different coating concentrations of (a) IgM and (b) LPS. (c and d)
Complement activation curve for different (c) HRP-conjugated anti-rabbit antibody dilutions and (d) rabbit polyclonal anti-human C3c antibody
dilutions. (e–g) Standard curves for (e) the classical pathways, (f) the lectin pathway and (g) the alternative pathway. Data (mean7SD) from
triplicates are representative of three independent experiments.
A C3c-based ELISA for identifying complement inhibitors 319dilution gave a better signal-noise ratio (410) and thus was
selected as the optimum dilution used in the assay (Fig. 1d).
Our assay was set up to screen complement inhibitors. For this
purpose, the optimum serum concentration should meet two require-
ments: 1) give a good signal to noise ratio; and 2) be reliable enough to
determine that the decreased OD is due to real inhibitory effects and
not false positive results caused by experimental errors, i.e., the
complement activation should not be too sensitive at the concentration
of interest in the standard curve. For the CP, the guinea pig serum
concentration was determined by varying the dilutions from 1:5 to
1:160. As can be seen in Fig. 1e, none of the dilutions presented good
stability. The dilutions of 1:5 and 1:10 had relatively higher OD value
and medium level of sensitivity compared with the dilution of 1:20.
According to the 3Rs principle (replacement, reduction and reﬁnement)
for experiments, the dilution of 1:10 was chosen instead of 1:5 so as to
consume less serum from guinea pigs. Similarly, a range of sera diluted
from 1:10 to 1:320 was conducted for the LP (Fig. 1f). The dilution of
1:20 for the LP was selected also due to reduced guinea pig sera
consumption and at this dilution, the assay demonstrated less variation.
However, for the AP (Fig. 1g), at high concentration of sera (1:2.5
dilution), the OD value was fairly low. All the sera including those
which were more diluted, showed almost no activation at all,
suggesting that this ELISA method might not be suitable for the
AP. Since the inhibitory effects of complement inhibitors on both the
CP and the AP can be studied via hemolytic assay, the following
experiments were mainly focused on the validation and application
of LP.3.2. Assay validation and application
After determining the optimal conditions for all parameters, we
moved on to evaluate the precision of our assay by studying the
inhibitory activities of tested compounds. Due to the shortcoming
of the hemolytic assay, there were no veriﬁed LP inhibitors
available for us to use as positive control. Therefore, we checkedthe reliability of the assay by measuring the IC50 of well-
characterized complement inhibitor suramin on the CP and
comparing it with the hemolytic assay. Suramin has been found
to inhibit at least six different enzymes in the complement systems
competitively, including C1, C2, C4 and serine proteases19. C2
and C4 play an important role in the CP, while serine proteases
(MASPs) are one of the most important components in the LP.
Suramin was tested starting from 2.5 mg/mL and then serially
diluted until 0.005 mg/mL. Based on the equation generated from
the inhibition potency curve obtained from the ELISA assay
(Fig. 2a), we determined that the IC50 of suramin on the CP is
0.08970.011 mg/mL, which is in agreement with literature reports
of a CH50 around 0.1 mg/mL determined by hemolytic assay
19.
This indicates that our ELISA assay gives reliable results that are
comparable to the results obtained by hemolytic assay.
Furthermore, we examined the reproducibility of the assay by
subjecting two classes of known complement inhibitors to the LP:
1) suramin, as a representative for synthesized compounds; and
2) BPs, a well-studied anti-complementary compound in our lab,
as a representative for colored natural products. The reproduci-
bility of the assay was determined by analyzing 3 replicates in a
single run for intra-assay precision and 3 independent replicates
for inter-assay accuracy. Suramin was tested within the same range
of concentrations as used for the CP and BPs were tested with ﬁnal
concentrations ranging from 0.156 to 5 mg/mL. Inhibitory effect
curves are presented in Fig. 2b and c. Results showed that both
suramin and BPs have anti-complement potency on the LP with a
determined IC50 value of 0.36870.071 mg/mL and 1.0577
0.003 mg/mL respectively. For both intra-assay and inter-assay
assessment of suramin and BPs, the obtained values of coefﬁcient
of variation (CV) are smaller than 30% (Table 1), and thus
ascertains a good reproducibility of the assay.
In addition to BPs, another polysaccharides extracted from
BCPs were also tested in our ELISA assay to study its inhibitory
effect on the LP. Similar to BPs, BCPs were tested ranging from
0.156 to 5 mg/mL as shown in Fig. 2d. The determined IC50 value
Figure 2 Assay validation and application with suramin, Bupleurum smithii var. parvifolium polysaccharides (BPs) and Bupleurum chinense
polysaccharides (BCPs). (a) Inhibitory effect of suramin on the classical pathway. (b) Inhibitory effect of suramin on the lectin pathway. (c)
Inhibitory effect of crude polysaccharides isolated from BPs on the lectin pathway. (d) Inhibitory effect of BCPs on the lectin pathway. Results are
expressed as percent inhibition (n¼3). Mean7SD is shown in duplicates and data are representative of three independent experiments.
Table 1 Determined IC50 values (mg/mL) and statistics data of suramin and BPs on the lectin pathway.
Sample ELISA assay (Mean, mg/mL) Standard deviation (SD) Coefﬁcient of variation (CV, %)
Inter-assaya Intra-assayb Inter-assay Intra-assay Inter-assay Intra-assay
Suramin 0.368 0.318 0.071 0.028 19.21 8.81
BPs 1.057 1.055 0.215 0.169 20.37 16.02
aThe inter-assay precision was analyzed in triplicate in 3 separate run.
bThe intra-assay precision was assessed by analyzing 3 replicates of each sample in a single run.
Mulu Wu et al.320of 0.9870.13 mg/mL indicated that the anti-complement potency
of BCPs was comparable to that of BPs.4. Discussion
In our study, a C3c-based ELISA assay was developed and
optimized for the determination of the inhibitory potency of
complement inhibitors against the classical and lectin activation
pathway. A schematic representation of the assay performance is
shown in Fig. 3.
Although the hemolytic assay remains as the golden standard in
the determination of inhibitory potency for complement inhibitors,
it is not applicable for the study of the LP. Due to the emerging
roles of the LP in clinical organ transplantation, infectious
diseases, auto-immune disorders and link with the coagulation
system20,21, it is of enormous importance to develop new assays to
evaluate complement inhibitors against the LP. Our ELISA assayfulﬁlls this demand thus providing new insights into the develop-
ment of anti-complementary compounds.
Moreover, this ELISA method is based on a 96-well plate,
allowing a large number of compounds to be tested in a single run.
Another advantage of our ELISA assay is that it is suitable for the
screening of colorful compounds. For the hemolytic assay, the
color of the compounds has an effect on the readout. Therefore,
control groups are needed to eliminate the background color of the
compound, which means larger amount of compounds are needed.
The ELISA method described here, on the other hand, is not
affected by the color of the compounds since they get washed off
during the process. In that case, less amount of compounds is
needed for the test, which is a big advantage especially when the
compounds to be tested are only available in small quantity as they
are difﬁcult to be synthesized or extracted.
Compared to the hemolytic assay, our ELISA method is more
reliable as the components used are commercially available and
hence the quality is assured. Also it has better reproducibility and
there is no batch-to-batch variation. In the hemolytic assay, sheep
Figure 3 Schematic of the C3c-based ELISA assay for complement inhibitor screening. Firstly, 96 well plates are coated overnight with
activation substrates for each respective pathway. After washing and blocking, pre-incubated mixture of guinea pig serum and the compound to be
tested are added into the wells. Next, rabbit polyclonal anti-C3c Abs will detect complement activation by binding to bound C3c, followed by
HRP-conjugated anti-rabbit Abs. Enzyme activity of HRP is assessed by measuring optical density (OD) after addition of OPD and H2O2.
Inhibitory effect is reﬂected by decreased OD compared with control group (without tested compounds).
A C3c-based ELISA for identifying complement inhibitors 321erythrocytes (SRBC) become increasingly fragile over time. For
optimal viability, the blood cells should be used within 7–14 days.
The source of SRBC varies, so it adds variation to the results from
batch to batch. However, the guinea pig serum used in our assay
can be prepared on a large scale and stored in 80 1C for a long
period.
Additionally, with available antibodies, this assay can be
adapted to capture other activation components in the complement
system, such as the membrane attack complex instead of C3c.
These adapted ELISA methods capturing different activated
components might provide better insight into the mechanism of
action of the inhibitors.
However, in our ELISA assay, the activation of complement
via the AP is much lower than the other two pathways. Even at a
serum concentration as high as 1:2.5, the OD values were less than
0.25 with a low signal-background ratio. For the lower concentra-
tions of sera, there was no activation at all. In our study, we used
LPS from Escherichia coli instead of Salmonella typhosa which
was used by Roos et al.4. Researchers showed that LPS puriﬁed
from different species, like E. coli, S. typhosa or Pseudomonas
aeruginosa, have different stimulatory effects on cytokine and
chemokine production due to their speciﬁc bacterial serotypes22.
Therefore, they might also behave differently when used as an
activator for the complement activation. In addition, they might
also have different binding afﬁnity to the 96-well plate. Future
study will be carried out using other serotypes of LPS, trying to
design and establish an appropriate ELISA method for the
alternative pathway.
For the validation of the method, instead of the traditionally
used complement inhibitor heparin, we used another well-studied
inhibitor suramin. As a biological agent, heparin has a compro-
mised stability and consistency. Our pilot experiments also
showed that heparin did not behave consistently against the CP
in ELISA method and no dose-dependent inhibition was observed
(data not shown). Suramin on the other side is a synthesizedcompound with good stability. It has been indicated to exhibit
inhibitory effect in the complement system as it targets at
various components including including C1, C2, C4 and serine
proteases19. For the CP, our ELISA assay showed an IC50 of
0.089 mg/mL, which is in agreement with a literature report
of a CH50 around 0.1 mg/mL determined by hemolytic assay
19.
For the LP, Fong et al.19 reported that suramin exhibited 90%
inhibition on serine proteases at 1 mmol/L, suggesting it had some
inhibitory effects on the LP considering the important role serine
proteases play in the LP. However, so far no inhibitory effect on
the full LP has been reported due to the lack of an adequate assay.
Our paper for the ﬁrst time reported that suramin indeed has
inhibition on the LP with an IC50 around 0.368 mg/mL. Validated
by suramin, our ELISA assay showed a good precision and
reproducibility.
In addition to synthesized compounds, we also used colored
natural products Bupleurum polysaccharides to examine whether
our assay is suitable for natural products, especially colored ones.
Radix Bupleuri, known as ‘Chai-Hu’, is one of the most frequently
prescribed crude herbs in traditional Chinese medicine for the
treatment of inﬂammatory diseases. Our previous experiments
demonstrated that the crude polysaccharides isolated from B.
smithii and B. chinense showed inhibitory properties towards
complement activation, involving both CP and AP8,23. However,
their inhibitory potency on the LP was not studied. Therefore, we
would like to determine the IC50 on the LP for these two crude
polysaccharides. Our ELISA assay showed that both BPs
(IC50¼1.057 mg/mL) and BCPs (IC50¼0.098 mg/mL) have inhi-
bitory effects on the LP and can be further studied for their
application in LP related diseases such as rheumatoid arthritis and
schizophrenia24,25. Together with the previous research results
(BPs: CH50¼0.34 mg/mL, AP50¼0.081 mg/mL23; BCPs:
CH50¼0.35 mg/mL, AP50¼0.337 mg/mL8), the inhibitory pro-
ﬁles of BPs and BCPs on the three complement activation
pathways are complete. These data demonstrated that both BPs
Mulu Wu et al.322and BCPs had strong anti-complementary properties on all three
activation pathways. However, their targets against the CP and AP
were different. BPs showed interaction with C1s, C3 and C423,
while BCPs blocked C1q, C2, C5 and C98, suggesting that the
mechanisms for their anti-complementary effects might be differ-
ent and diverse. More comprehensive experiments, which allow
direct assessment of the interaction between these two polysac-
charides and their targets in the lectin activation cascade, are
required to further demonstrate the similarity and difference
between BPs and BCPs.
In conclusion, the ELISA assay described in this study is a
simple high throughput screening approach for the determination
of complement inhibitors. The assay is robust and reliable based
on the validation results. Most importantly, it might be a promising
approach to further study the mechanisms of complement inhibi-
tors. We also showed that the previously identiﬁed CP and AP
inhibitors suramin, Bupleurum smithii var. Parvifolium polysac-
charides and Bupleurum chinense polysaccharides also have good
anti-complement potency on the LP.
Acknowledgments
This work was supported by grants from the National Natural
Science Foundation of China (Nos. 81274165, 81330089 and
30925042), the State Key Program for Innovative Drugs from the
Ministry of Science and Technology of the people’s Republic of
China (No. 2012ZX09301001-003), the Science and Technology
Commission of Shanghai Municipality (Nos. 12JC1400800 and
10XD1405900), and Fudan's Undergraduate Research Opportu-
nities Program (Xiyuan, No. 102305).
References
1. Trouw LA, Daha MR. Role of complement in innate immunity and
host defense. Immunol Lett 2011;138:35–7.
2. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, et al.
Interaction between the coagulation and complement system. Adv Exp
Med Biol 2008;632:71–9.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key
system for immune surveillance and homeostasis. Nat Immunol
2010;11:785–97.
4. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC,
Fallaux-van den Houten FC, et al. Functional characterization of the
lectin pathway of complement in human serum. Mol Immunol
2003;39:655–68.
5. Herpers BL, de Jong BA, Dekker B, Aerts PC, van Dijk H, Rijkers GT,
et al. Hemolytic assay for the measurement of functional human
mannose-binding lectin: a modiﬁcation to avoid interference from
classical pathway activation. J Immunol Methods 2009;343:61–3.
6. Cedzynski M, Swierzko AS, Kilpatrick DC. Factors of the lectin
pathway of complement activation and their clinical associations in
neonates. J Biomed Biotechnol 2012;2012:363246.
7. Wallis R. Interactions between mannose-binding lectin and MASPs
during complement activation by the lectin pathway. Immunobiology
2007;212:289–99.8. Di H, Zhang Y, Chen D. An anti-complementary polysaccharide
from the roots of Bupleurum chinense. Int J Biol Macromol
2013;58:179–85.
9. Zwirner J, Wittig A, Kremmer E, Götze O. A novel ELISA for the
evaluation of the classical pathway of complement. J Immunol
Methods 1998;211:183–90.
10. Fredrikson GN, Truedsson L, Sjöholm AG. New procedure for the
determination of complement deﬁciency by ELISA. Analysis of
activation pathways and circumvention of rheumatoid factor inﬂuence.
J Immunol Methods 1993;166:263–70.
11. Petersen SV, Thiel S, Jensen L, Steffensen R, Jensenius JC. An assay
for the mannan-binding lectin pathway of complement activation.
J Immunol Methods 2001;257:107–16.
12. Sarma JV, Ward PA. The complement system. Cell Tissue Res
2011;343:227–35.
13. Webster RO, Larsen GL, Henson PM. In vivo clearance and tissue
distribution of C5a and C5a des arginine complement fragments in
rabbits. J Clin Invest 1982;70:1177–83.
14. Teisner B, Brandslund I, Grunnet N, Hansen LK, Thellesen J, Svehag
SE. Acute complement activation during an anaphylactoid reaction to
blood transfusion and the disappearance rate of C3c and C3d from the
circulation. J Clin Lab Immunol 1983;12:63–7.
15. Palarasah Y, Skjodt K, Brandt J, Teisner B, Koch C, Vitved L, et al.
Generation of a C3c speciﬁc monoclonal antibody and assessment of
C3c as a putative inﬂammatory marker derived from complement
factor C3. J Immunol Methods 2010;362:142–50.
16. Bier OG, Leyton G, Mayer MM, Heidelberger M. A comparison of
human and guinea pig complements and their component fractions.
J Exp Med 1945;81:449–68.
17. Trouw LA, Seelen MA, Duijs JM, Wagner S, Loos M, Bajema IM,
et al. Activation of the lectin pathway in murine lupus nephritis. Mol
Immunol 2005;42:731–40.
18. Jiang YW, Li H, Zhang YY, Li W, Jiang YF, Ou YY, et al. Beneﬁcial
effect of Bupleurum polysaccharides on autoimmune-prone MRL-lpr
mice. Clin Dev Immunol 2012;2012:842928.
19. Fong JS, Good RA. Suramin-a potent reversible and competitive
inhibitor of complement systems. Clin Exp Immunol 1972;10:
127–38.
20. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement
dysregulation and disease: from genes and proteins to diagnostics and
drugs. Immunobiology 2012;217:1034–46.
21. Degn SE, Jensenius JC, Bjerre M. The lectin pathway and its
implications in coagulation, infections and auto-immunity. Curr Opin
Organ Transplant 2011;16:21–7.
22. Mathiak G, Kabir K, Grass G, Keller H, Steinringer E, Minor T, et al.
Lipopolysaccharides from different bacterial sources elicit disparate
cytokine responses in whole blood assays. Int J Mol Med 2003;11:41–4.
23. Xu H, Zhang Y, Zhang J, Chen D. Isolation and characterization of an
anti-complementary polysaccharide D3-S1 from the roots of
Bupleurum smithii. Int Immunopharmacol 2007;7:175–82.
24. Ammitzboll CG, Thiel S, Ellingsen T, Deleuran B, Jorgensen A,
Jensenius JC, et al. Levels of lectin pathway proteins in plasma and
synovial ﬂuid of rheumatoid arthritis and osteoarthritis. Rheumatol Int
2012;32:1457–63.
25. Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB.
Increased complement classical and mannan-binding lectin pathway
activities in schizophrenia. Neurosci Lett 2006;404:336–41.
